Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, announced that the first patient has been successfully dosed in the Phase I/IIa clinical trial of ABI-110, the company's first gene therapy drug for the treatment of Wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV).

"We are thrilled to announce this significant milestone in the clinical investigation of ABI-110" said Shawn Liu, Ph.D., Chief Executive Officer of Avirmax Biopharma Inc. "ABI-110 has the potential to revolutionize the treatment landscape for Wet AMD and PCV."

"Dosing the first patient marks a pivotal step forward in Avirmax's mission to bring transformative gene therapies to patients suffering from severe retinal diseases.," said Wendy Murahashi, M.D., Chief Medical Officer of Avirmax Biopharma Inc..

Wet Age-related Macular Degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV) are serious retinal diseases that can lead to severe vision loss. Current treatments often require frequent injections and provide only temporary relief. ABI-110 has the potential to offer a more durable and effective solution by addressing the root causes of these conditions at the genetic level.

ABI-110, Avirmax Biopharma's proprietary gene therapy, utilizes an engineered capsid, AAV2.N54, to efficiently deliver therapeutic transgene to the macular retina. This approach aims to provide a long-lasting solution that goes beyond the limitations of current treatments. The Phase 1 clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of ABI-110 in patients with Wet AMD and PCV.